New database to help track quality of medicines in global markets

Apr 05, 2011

In the growing global battle against substandard and counterfeit medicines, the Promoting the Quality of Medicines (PQM) program has launched a new, public database of medicines collected and analyzed in collaboration with stakeholders from countries in Africa, South America and Southeast Asia. Free of charge and available to anyone with access to the internet, the Medicines Quality Database (MQDB) includes information on the quality of medicines collected from a variety of sources. To date, more than 8700 records of tested samples collected from Ghana, Laos, Vietnam, Cambodia, the Philippines, Thailand, Peru, Guyana and Colombia have been entered into the database.

Supported by USAID and implemented by the U.S. Pharmacopeial Convention (USP), PQM provides technical assistance to help strengthen quality assurance of medicines in developing countries primarily in Sub-Saharan Africa, Southeast Asia, Latin America, and the Caribbean, as well as Russia. PQM has a special emphasis on verifying and improving the availability of quality medications intended to treat life-threatening diseases such as malaria, HIV/AIDS and tuberculosis. The MQDB will assist in-country health authorities and the general public through evidence-based data on poor-quality medicines circulating in several regions of the world.

Data on the collected and tested samples recorded in the new database include:

  • Geographic location – country and province/state in which a sample was found
  • Date of sampling (by year)
  • Facility from which sample was collected – organized by sector (i.e., public, private or informal) and type (e.g., pharmacy, hospital, clinic)
  • Medicine information – product name, manufacturer name, therapeutic indication, active pharmaceutical ingredient, dosage form, batch/lot number
  • Test result (i.e., "passed" or "failed" with regard to authenticity)
  • Substandard/counterfeit status (i.e., "yes" or "no", depending on a country's classification for substandard or counterfeit medicines).
According to Patrick Lukulay, Ph.D., USP's director of the PQM program: "Pharmaceutical markets operate globally, and sharing information on the quality of medicines among and within countries is crucial to patients, regulatory authorities, pharmacies, and manufacturers as well as agencies and organizations involved in international procurement and distribution of medicines. Having a publicly-available database that provides quick and easy access to information on medicines tested for their authenticity is a vital tool in helping to protect the public against the threat of substandard and counterfeit drugs."

Information in the MQDB is collected from health authorities responsible for testing the quality of medicine samples in a given country. Data on tested samples are included in the MQDB only after verification for accuracy. As a central repository for information sourced from different parts of the world, the database will provide with an additional tool for surveillance of the quality of locally-acquired as well as imported medicines delivered through a global supply chain.

As more poor-quality medicines—both substandard and counterfeit—make their way into pharmacies and other outlets in developing countries, there is a higher risk to the health of people exposed to those medicines. Poor-quality medicines may bring little or no relief to patients, and may contribute to resistance to treatments for which there are no foreseeable alternatives in the near future. Additionally, patients may begin to lose confidence in the public health system, making them reluctant to seek proper medical help when most needed.

"While multiple lines of intervention are critical for eliminating diseases like malaria, wide dissemination of information about poor quality medicines and their sources is vital in addressing the threats posed by the development of drug resistance to progress in disease control," said Dr. Jaime Chang, M.D., project management specialist from the Health Office of USAID-Peru and coordinator of the Amazon Malaria Initiative (AMI), supported by USAID. "The new database has broader applicability than malaria, of course, including invaluable data on tuberculosis and HIV/AIDS medications as well. However, in AMI's expanding efforts to contain and eventually eliminate malaria, an easily-accessible and reliable surveillance database like MQDB will be a great support in accomplishing our goals. I'm certain that those combating all three diseases around the world will find this database equally useful."

Explore further: New sleeping pill poised to hit US markets

More information: To access the Medicines Quality Database online, go to: www.usp.org/worldwide/medQualityDatabase/

add to favorites email to friend print save as pdf

Related Stories

Bad malaria pills in Africa raise resistance fears

Feb 08, 2010

(AP) -- High rates of the most effective type of malaria-fighting drugs sold in three African countries are poor quality - including nearly half the pills sampled in Senegal - raising fears of increased drug resistance that ...

Recommended for you

New sleeping pill poised to hit US markets

2 hours ago

An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.

Global recommendations on child medicine

3 hours ago

Transparent information on the evidence supporting global recommendations on paediatric medicines should be easily accessible in order to help policy makers decides on what drugs to include in their national drug lists, according ...

FDA has safety concerns on Merck insomnia drug

May 20, 2013

Federal health regulators say an experimental insomnia drug from Merck can help patients fall asleep, but it also carries worrisome side effects, including daytime drowsiness and suicidal thinking.

US adviser on board of firm that sold anthrax drug

May 20, 2013

(AP)—Former Navy Secretary Richard J. Danzig, who has served as a bio-warfare adviser to the president, the Pentagon, and the Department of Homeland Security, urged the government to stockpile an anti-anthrax drug while ...

User comments : 0

More news stories

If you can remember it, you can remember it wrong

(Medical Xpress)—Native peoples in regions where cameras are uncommon sometimes react with caution when their picture is taken. The fear that something must have been stolen from them to create the photo ...

B vitamins could delay dementia

(Medical Xpress)—Despite spending billions of dollars on research and development, drug companies have been unable to come up with effective treatments for dementia and Alzheimer's Disease (AD). Now, A. ...

Reducing caloric intake delays nerve cell loss

Activating an enzyme known to play a role in the anti-aging benefits of calorie restriction delays the loss of brain cells and preserves cognitive function in mice, according to a study published in the May ...

New sleeping pill poised to hit US markets

An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.

Changing cancer's environment to halt its spread

By studying the roles two proteins, thrombospondin-1 and prosaposin, play in discouraging cancer metastasis, a trans-Atlantic research team has identified a five-amino acid fragment of prosaposin that significantly reduces ...

New method for producing clean hydrogen

Duke University engineers have developed a novel method for producing clean hydrogen, which could prove essential to weaning society off of fossil fuels and their environmental implications.